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Abstract
Objective: Clinical neurological assessment is challenging for severe traumatic
brain injury (TBI) patients in the acute setting. Waves of neurochemical abnor-
malities that follow TBI may serve as fluid biomarkers of neurological status.
We assessed the cerebrospinal fluid (CSF) levels of glutamate, lactate, BDNF,
and GDNF, to identify potential prognostic biomarkers of neurological out-
come. Methods: This cross-sectional study was carried out in a total of 20 con-
secutive patients (mean [SD] age, 29 [13] years; M/F, 9:1) with severe TBI
Glasgow Coma Scale ≤ 8 and abnormal computed tomography scan on admis-
sion. Patients were submitted to ventricular drainage and had CSF collected
between 2 and 4 h after hospital admission. Patients were then stratified
according to two clinical outcomes: deterioration to brain death (nonsurvival,
n = 6) or survival (survival, n = 14), within 3 days after hospital admission.
Received: 23 February 2017; Accepted: 31
March 2017
CSF levels of brain-derived substances were compared between nonsurvival and
survival groups. Clinical and neurological parameters were also assessed.
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Results: Glutamate and lactate are significantly increased in nonsurvival relative
to survival patients. We tested the accuracy of both biomarkers to discriminate
patient outcome. Setting a cutoff of >57.75, glutamate provides 80.0% of sensi-
tivity and 84.62% of specificity (AUC: 0.8214, 95% CL: 54.55–98.08%; and a
cutoff of >4.65, lactate has 100% of sensitivity and 85.71% of specificity (AUC:
0.8810, 95% CL: 54.55–98.08%). BDNF and GDNF did not discriminate poor
outcome. Interpretation: This early study suggests that glutamate and lactate
concentrations at hospital admission accurately predict death within 3 days
after severe TBI.
Introduction
Traumatic brain injury (TBI) is a leading cause of mortal-
ity and morbidity among young individuals in low- and
middle-income countries. In Brazil, the estimated inci-
dence of TBI is 400 cases per 100.000 inhabitants.1 TBI sur-
vivors, commonly suffer persisting cognitive dysfunction,
and have a heightened risk of premature death, progressive
neurodegeneration, and Alzheimer’s disease.2,3 The patho-
physiological mechanisms governing short- and long-term
TBI outcomes include axonal injury3, blood-brain barrier
disruption4, glutamate neurotoxicity5, neuroenergetic defi-
cits6, and lack of neurotrophic support.7 These neuro-
chemical signatures also provide an opportunity for
identifying molecules in body fluids that may serve as can-
didate biomarkers with putative clinical relevance.8,9
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Glutamate, the predominant excitatory neurotransmit-
ter in the mammalian brain, may become excitotoxic at
high extracellular concentrations through overstimulation
of glutamate receptors.5,10 Remarkably, high concentra-
tions of extracellular glutamate are commonly observed
after severe TBI, the magnitude of which correlates with
increased intracranial pressure (ICP) and poor clinical
outcomes.11–14 Immediately after TBI, there is an exacer-
bated glutamate-induced neuronal calcium influx and
ionic imbalance, which evokes membrane depolarization
and further glutamate release. As consequence, the mem-
brane pumps work to rapidly restore the membrane gra-
dients thereby increasing the glucose flux through
glycolytic pathway and lactate production.8,10 However,
extracellular lactate may arise not only from neuronal gly-
colysis. The astrocyte-neuron lactate shuttle model pro-
poses a metabolic coupling between astrocytes and
neurons based on the glutamate-stimulated glycolysis in
astrocytes, and the extrusion of lactate to support the
energy demands associated with increased neuronal activ-
ity.15 Based on this concept, one could argue that
increased extracellular brain lactate concentrations after
TBI may reflect increased astrocytic metabolic responsive-
ness to high glutamate concentrations. This mechanism
seems to be important for the survival of severe TBI
patients since hypertonic sodium lactate infusion
improves ICP, hemodynamic, and energetic parame-
ters16,17, whereas disturbances in this metabolic coupling
are associated with worse prognosis.18
Moreover, experimental studies have demonstrated that
in response to increased extracellular glutamate levels,
astrocytes and neurons release brain-derived neurotrophic
factor (BDNF) and the glial cell line-derived neurotrophic
factor (GDNF). Notably, both of these neurotrophins
modulate the activity of glutamatergic neurotransmission,
which includes neuronal synaptic release and astrocytic
glutamate uptake transporters activity/expression19,20,
while BDNF specifically modulates the expression of the
high-affinity monocarboxylate transporters 2 (MCT2) in
neurons.21 The MCT2 controls the influx of energetic
substrates including lactate to the oxidative metabolism in
neurons.21 Based on the aforementioned, increased con-
centration of these molecules could likely indicate trophic
responses intending to halt glutamatergic toxicity and
improve metabolic support.
Although not yet shown in TBI patients, demonstration
of a mechanistic interaction between neurotrophins, lac-
tate, and glutamate neurotransmission may shed light on
the high incidence of death in the initial days after a sev-
ere TBI. In addition, this interaction may provide an
opportunity to evaluate relative concentrations of neu-
rotrophins and glutamate levels as potential biomarkers
with prognostic value. Indeed, since clinical neurological
assessment is challenging for severe TBI patients in the
acute setting, due to the common comatose state, etc.,
fluid biomarkers are being vigorously pursued.
Therefore, in this study, we assessed the cerebrospinal
fluid (CSF) concentrations of glutamate, lactate, BDNF,
and GDNF at hospital admission, to identify prognostic
biomarkers of clinical outcomes.
Subjects and Methods
Study population and clinical management
The cohort used in this study was previously established
in B€ohmer et al., 20112. Briefly, a cross-sectional study
was carried out between 2006 and 2009 with a total of 20
consecutive patients with severe TBI, presenting score 8
or less in Glasgow Coma Scale (GCS) and abnormal com-
puted tomography (CT) scan on their admission to the
Emergency Unit of Cristo Redentor Hospital (Porto Ale-
gre, RS, Brazil). CT classification was performed accord-
ing to Eisenberg et al., 199022. Further details regarding
patient’s CT on admission were available on B€ohmer
et al., 20112. The TBI patients were predominantly young
male (mean [SD] age, 29 [13] years; M/F, 9:1) and were
admitted to emergency mainly because of motor vehicle
accidents. The inclusion criteria for participating in this
study was patients with isolated severe TBI, with no pre-
vious history of inflammatory, metabolic, and neuropsy-
chiatric disorders that could influence the biomarkers’
concentrations and clinical outcomes. The exclusion crite-
ria were diabetes, drug abuse, and neuropsychiatric disor-
ders. The characteristics of patients are shown in Table 1.
Severe TBI patients were submitted to Hospital Cristo
Redentor emergency clinical protocol as previously
reported by our group2. Briefly, after intubation, patients
were supported with continuous mild hyperventilation
induced with arterial carbon dioxide tension (PaCO2
between 30 and 35 mmHg). Mean arterial pressure was
kept at satisfactory levels to allow cerebral perfusion pres-
sure (mean arterial blood pressure minus intracerebral
pressure) above 60 mmHg. Immediately after initial
resuscitation, one intracranial pressure monitor (Cod-
man microsensor) was introduced into the brain par-
enchyma through a right frontal trepanation.
Ventriculostomy was performed to monitor ICP and to
allow drainage of CSF when the ICP exceeded 20 mmHg,
which was the proposed protocol of Brain Trauma Foun-
dation for clinical management of severe TBI patients
with GCS of 8 or less and abnormalities on the computed
tomography. The clinical management followed the same
standard protocol for ICP management in all patients.
CSF drained from the intraventricular catheter was col-
lected via an extraventricular drainage system. The
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intraventricular catheter was removed when patients died,
or when survival patients presented stable ICP for 24 h.
The primary ventricular CSF samples collected between 2
and 4 h after hospitalization were used to determine
biomarkers’ concentrations. For an overview about advan-
tages and disadvantages of CSF as a matrix to measure
candidate biomarkers of brain injury, please see Zetteberg
et al., 2016.23
Intracranial mass lesions associated with midline dis-
placement greater than 5 mm were surgically removed
when necessary. No undesirable complications associated
with intraventricular catheter placement or ICP monitor-
ing including intracranial hemorrhage or infection were
observed. Intracranial hypertension was managed initially
in all patients by conventional ICP reduction therapy,
such as CSF drainage, mannitol bolus, and mild hyper-
ventilation (PaCO2 up to 30 mmHg). In patients with
sustained high ICP (from 20 mmHg) and unresponsive
to conventional therapy, other alternatives were
employed, including barbiturate coma, hyperventilation
(PaCO2 < 30 mmHg), control with jugular bulb monitor-
ing, and decompress craniotomy.
Moreover, 20 healthy subjects (ASA I status) scheduled
for elective urological, gynecological, general, or vascular
procedures were selected as age and sex-matched controls.
Surgeries essentially included inguinal or umbilical
herniorrhaphy, perineoplasty, abdominal hysterectomy,
vaginal hysterectomy, myomectomy, transurethral pros-
tate or bladder resection, prostatectomy, and saphenec-
tomy. These subjects were interviewed for the absence of
cognitive or neurological disorders.2 Control subjects
received a spinal anesthesia technique. Experienced anes-
thesiologists collected the CSF. The first 0.5 mL of CSF
aspirated was discarded to reduce cells contamination.
The CSF samples were inspected visually and discarded if
blood contamination was present. A total of 0.5 mL of
CSF was collected from the patients after successful sub-
arachnoid puncture and before the intrathecal injection of
anesthetics or analgesics. The CSF samples from patients
and controls were immediately centrifuged at 10,000g in
an Eppendorf centrifuge during 5 min to obtain cell-free
supernatants and stored at 70°C within 30 min of
collection.
Informed consent for participating in this study was
obtained from patients’ family members and directly from
healthy individuals, according to the Declaration of Hel-
sinki. At the moment when the consent form was applied,
family members were also questioned about patient’s life-
style and preexistent diseases. The local institutional
Ethics Committee approved this protocol (project number
0038.0.164.165-05).
Outcome measures
Considering that patients died up to 3 days from hospi-
tal admission, we decided to use 3 days as an arbitrary
cutoff point. Patients were then stratified according to
two clinical outcomes: deterioration to brain death
(nonsurvival n = 6) or survival (survival, n = 14),
within 3 days after hospital admission. The ICP, hemo-
dynamic, and metabolic variables including mean arte-
rial blood pressure and cerebral perfusion pressure were
daily assessed.22 Two years after discharge, phone calls
were placed to confirm that survival patients remained
alive, and to investigate the grade of long-term func-
tional disability. TBI patients were then assessed for the
modified Rankin Scale (mRS) and scored by an experi-
enced neurologist (R.M). The mRS score is the com-
monly used outcome classification scale for disabilities
and handicaps after cerebral stroke or other causes of
neurological disability. The scale has six grades ranging
from 0 (fully independent) to grade 6 (dead), and is
considered a reliable endpoint for clinical neurological
studies.24
CSF Biomarkers analysis
Glutamate assay
Glutamate concentration in TBI patients and controls
were analyzed in 25 lL of the CSF cell-free supernatant
samples through high-performance liquid chromatogra-
phy (HPLC). Briefly, samples were filtered and derivatized
with o-phthalaldehyde and mercaptoethanol. CSF samples
were separated by reverse phase column (Supelcosil LC-
18, 250 mm 9 4.6 mm, Supelco) in a Shimadzu Instru-
ments liquid chromatograph. The mobile phase flowed at
a rate of 1.4 mL/min at 24°C. Buffer composition is A:
Table 1. Demographics and clinical characteristics of patients.
Variables
Survival (n = 14)
(median  range)
NonSurvival (n = 6)
(median  range) P -value
Age 29 (17–53) 21.5 (16–38) P = 0.140
ICP 8.5 (3–20) 10 (2–45) P = 0.095
MAP 93 (70–124) 92.5 (63–113) P = 0.534
CPP 87.5 (57–114) 82 (21–88) P = 0.149
GCS 6 (4–8) 4 (4–7) P = 0.085
CSF
glucose
(mg/dL)1
108.2 (75.9–129.4) 118.3 (80.7–191.9) P = 0.341
ICP, intracranial pressure; MAP, mean arterial pressure; CPP, cerebral
perfusion pressure; GCS, Glasgow coma scale.
1CSF glucose levels (controls): median: 55.29 range: 29.8–94.1
mg/dL.
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0.04 mol/L sodium dihydrogen phosphate monohydrate
buffer, pH 5.5, containing 20% of methanol; and B:
0.01 mol/L sodium dihydrogen phosphate monohydrate
buffer, pH 5.5, containing 80% of methanol. The gradi-
ent profile was modified according to the content of
buffer B in the mobile phase: 0% at 0.00 min, 25% at
13.75 min, 100% at 15.00–20.00 min, and 0% at 20.01–
25.00 min. Absorbance was read in a Shimadzu fluores-
cence detector, with excitation and emission being
360 nm and 455 nm, respectively. The concentration
was expressed in lmol/L.22
Lactate, BDNF, and GDNF assays
The lactate level was measured using a commercial kit
manufactured by Interteck-Katal Biotechnology, Brasil.
Calibration factors were determined using a standard of
lithium lactate (4.44 mmol/L). Lactate concentration is
expressed as mmol/L (24). The levels of BDNF and
GDNF were assayed using commercially available
enzyme-linked immunosorbent assay kits (ELISA) (BDNF
ref. DBNT00 and GDNF ref. DY212; R&D Systems Inc.,
Minneapolis, MN, USA.). The CSF concentrations of
BDNF or GDNF were determined by measuring the
absorbance of standard and samples at 450 nm with a
SpectraMax M5 (Molecular Devices). The calibration
curve was linear up to 1000 pg/mL for BDNF, and up to
2000 pg/mL to GDNF (25). The concentrations are
expressed as pg/mL. All samples and standards were car-
ried out in duplicate within the same experiment, and the
variation within each duplicate was <5%.
Statistical analysis
We submitted data to Kolmogorov–Smirnov testing for
normality evaluation. Glutamate, lactate, BDNF, and
GDNF values were fitted in a standard distribution curve
and were therefore subjected to nonparametric analyses.
Comparisons between groups were performed by two-
tailed Mann–Whitney test. ROC curves were created to
explore the ability of biomarkers to predict survival and
nonsurvival patients after severe TBI. Estimates of the
areas under the curves (AUCs) were obtained, with an
AUC of 0.5 indicating no discrimination and an AUC
of 1.0 indicating a perfect diagnostic test. Bivariate cor-
relations among biomarkers were performed by Spear-
man correlation test. Spearman cross-correlation analyses
among biomarkers was also performed and corrected by
Bonferroni Method. All numerical variables are pre-
sented as mean  standard deviation (S.D.). P values
at ≤ 0.05 were considered statistically significant. All
analyses were performed using GraphPad Prism 5.0 or
Matlab 2014b.
Results
CSF biomarkers glutamate, lactate, BDNF,
and GDNF
The level of the excitatory neurotransmitter glutamate in
TBI patients (nonsurvival: median [IQR]: 61.25 [41.40–
88.20] lmol/L and survival: 25.35 [5.00–93.70] lmol/L)
was significantly higher than control group (median
[IQR]: 2.6 [2.1–3.3] lmol/L) (P < 0.0001). Also, gluta-
mate levels were significantly increased in nonsurvival
relative to survival patients (P = 0.0256) (Fig. 1A).
Similarly, we found that CSF lactate levels in TBI group
were significantly increased compared with control group
(median [IQR]: 1.5 [0.4–2.8] mmol/L) (P < 0.0001). Fur-
ther, there was a significant difference in lactate level
between nonsurvival (median [IQR]: 6.05 [5.00–9.10]
mmol/L) relative to survival group (median [IQR]: 3.6
[1.6–8.1] mmol/L) (P = 0.0060) (Fig. 1B).
In contrast to glutamate and lactate, while CSF BDNF
levels in TBI patients were significantly different from
control group (median [IQR]: 190.8 [161.0–210.4] pg/mL
(P = 0.0001), BDNF levels in nonsurvival (median [IQR]:
263.0 [216.5–311.9] pg/mL) were not significantly differ-
ent from survival group (median [IQR] 231.7 [174.0–
552.6] pg/mL) (P = 0.4072) (Fig. 1C).
Moreover, there was no significant difference in CSF
GDNF levels between control (median [IQR]: 338.9
[306.8–440.9] pg/mL) and TBI, and between nonsurvival
(median [IQR]: 317.7 [303.0–473.9] pg/mL) and survival
patients (median [IQR] 351.7[287.6–788.7] pg/mL
(P = 0.3015) (Fig. 1D).
The dynamic heat map (Fig. 1E) provides a visualiza-
tion of the biomarker signatures. We can visualize that
both lactate and glutamate displayed a distinct profile in
the survival and nonsurvival patients, whereas BDNF and
GDNF showed no evident discriminatory profile.
CSF biomarkers and bivariate correlation
analysis
To provide insights regarding the quantitative relationship
between biomarkers, we tested the correlation coefficient
in the TBI and Control groups pooled together. There was
significant statistical correlation between CSF levels of glu-
tamate and lactate (r = 0.7051; P = 0.053; Fig. 2A), gluta-
mate and BDNF (r = 0.6983; P = 0.024) (Fig. 2B), and
BDNF and lactate (r = 0.7491; P = 0.039) (Fig. 2D). The
correlations between GDNF and glutamate (r = 0.01794;
P = 0.462) (Fig. 2C), GDNF and BDNF (r = 0.004; P =
0.574) (Fig. 2F), and GDNF and lactate (r = 0.1368;
P = 0.513) (Fig. 2E) did not reach statistical significance.
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Figure 1. Cerebrospinal fluid biomarkers in controls and severe TBI patients (survival and nonsurvival). The CSF levels of glutamate (A), lactate
(B), and BDNF (C) in TBI group at hospital admission were significantly different than control group (n = 20 per group, ****P > 0.0001). In
addition, glutamate and lactate levels were significantly higher in nonsurvival (n = 6) relative to survival patients (n = 14) (*P = 0.0256 and
**P = 0.0060, respectively). The GDNF level was not different between control and TBI groups, (D). Both BDNF (C, right panel) and GDNF (D,
right panel) were not different between survival and nonsurvival TBI patients. The dynamic heatmap shows a neurochemical signature regarding
the profile of the biomarkers in control subjects and TBI patients (E). Horizontal lines indicate median and interquartile range. The dynamic
heatmap scale represents normalized (log) percent of change in relation to controls.
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The statistical correlations between the CSF biomarkers
and clinical outcomes are showed in Table 2. There were
no significant correlations between fluid biomarkers con-
centrations at admission and clinical outcomes measured
up to 3 days after hospital admission. In contrast, gluta-
mate and lactate were significantly correlated with modi-
fied Rankin Scale (mRS). Correlation coefficients for
Glutamate vs. mRS, and Lactate vs. mRS were
(r = 0.6427, P = 0.002) and (r = 0.4635, P = 0.03),
respectively.
ROC curves and biomarkers associations
Given the CSF concentrations of glutamate and lactate
showed the highest level in nonsurvival patients, we evalu-
ated the accuracy of those tests as early prognostic
biomarkers of neurological deterioration. The area under
the ROC curve (AUC) indicate how well glutamate and lac-
tate can discriminate patients that will survive from
patients that will evolve to death up 3 days in the intensive
unit care. The ROC curve was achieved from glutamate
and lactate up to 3 days from admission in relation to
death (Fig. 3A and B). The specificity rate is showed in
function of sensitivity rate at different cutoff points. Setting
Figure 2. Spearman bivariate correlation analyses between cerebrospinal fluid biomarkers. There were statistically significant correlations between
glutamate and lactate (A) (r = 0.7051; P = 0.053), glutamate and BDNF (B) (r = 0.6983; P = 0.024), Lactate and BDNF (D)(r = 0.7491; P = 0.039).
GDNF did not show statistically significant correlations with glutamate (C), lactate (E), and BDNF (F).
Table 2. Correlation between CSF biomarkers and clinical outcomes
in TBI survival and nonsurvival groups.
Variables Spearman (r) P -value
Glutamate vs. ICP 0.34 0.15
Lactate vs. ICP 0.09 0.72
BDNF vs. ICP 0.16 0.50
GDNF vs. ICP 0.20 0.41
Glutamate vs. MAP 0.21 0.37
Lactate vs. MAP 0.01 0.98
BDNF vs. MAP 0.05 0.84
GDNF vs. MAP 0.21 0.37
Glutamate vs. CPP 0.36 0.12
Lactate vs. CPP 0.15 0.53
BDNF vs. CPP 0.18 0.46
GDNF vs. CPP 0.01 0.96
Glutamate vs. GCS 0.15 0.54
Lactate vs. GCS 0.39 0.09
BDNF vs. GCS 0.13 0.58
GDNF vs. GCS 0.16 0.49
ICP, Intracranial pressure; BDNF, brain-derived neurotrophic factor;
GDNF, glial cell line-derived neurotrophic factor; MAP, Mean arterial
pressure; CPP, Cerebral perfusion pressure; GCS, Glasgow coma
scale.
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a cutoff of >57.75, glutamate provides 80% of sensitivity
and 84.62% of specificity (AUC: 0.8214, 95% CI, CL:
54.55% to 98.08%) and with a cutoff of >4.650, lactate has
100% of sensitivity and 85.71% of specificity (AUC:
0.8810, 95% CI, CL: 54.55–98.08%). Glutamate and lactate
provide high specificity and sensitivity, with almost identi-
cal power, for predicting brain death in TBI patients.
Additionally, aiming to corroborate the proposed func-
tional interplay among biomarkers, we have developed a
network using cross-correlation analysis. We identified
statistically significant associations among glutamate, lac-
tate, and BDNF. One may propose that these associations
suggest reactive neuronal and glial responses to injury,
and ultimately may reflect some level of functional
coupling (Fig. 4).
Discussion
This study used a multi-biomarker approach in the CSF
of severe TBI patients searching for neuroactive sub-
stances with potential clinical and prognostic relevance.
Our results demonstrated that CSF levels of glutamate,
lactate, and BDNF at hospital admission have potential
value as biomarkers of severe head injury. Further, gluta-
mate and lactate levels were able to predict with high sen-
sitivity and specificity patients who will die within 3 days
following severe TBI. Also, up to 3 days, the clinical out-
comes including intracranial pressure (ICP), mean arterial
pressure, cerebral perfusion pressure, and GCS were simi-
lar between TBI groups (nonsurvival vs. survival) and did
not correlate with CSF biomarkers.
The role of glutamate as biomarker of brain injury and
clinical outcomes has previously been explored in studies
with severe TBI patients. In contrast to our findings,
Brown et al., 199825 showed that despite the persistent
increase in the CSF glutamate levels up to 5 days after
severe TBI, these changes did not predict brain death or
correlate with GCS and electrophysiological deterioration.
However, the majority of clinical studies indicate that
increased brain extracellular glutamate levels in associa-
tion with comorbidities may predict poor functional out-
comes and brain death.11–14 For instance, secondary
mechanisms associated with the brain tissue deformation
including global ischemia, sustained increased intracranial
pressure and focal contusions11,13, and spontaneous brain
hypothermia (<36°C)26 have been implicated in the
increase in glutamate levels and acute neuronal death.
Also, increased extracellular brain glutamate concentra-
tion after TBI is also influenced by decreased astrocytic
glutamate uptake.27 This might indicate that different
players associated to the tripartite glutamatergic synapse,
likely contribute for the deterioration of brain function
after severe TBI, such as disrupted energy support rapidly
triggering neuronal death.
We found that CSF lactate levels at hospital admission
predict severe TBI patients who will die within 3 days
after hospitalization. As previously stated, astrocytes take
up glutamate in the synaptic space thereby triggering gly-
colysis and lactate production, which is shuttled to neu-
rons.15 The flux of these substrates in the body fluids has
been explored in the clinical setting as biomarkers of neu-
roenergetic support, neuron-to-astrocyte interactions, and
clinical outcomes.28 Recently, Thelin et al., 2014 showed
that an increased brain extracellular levels of lactate and
pyruvate after TBI were correlated with unfavorable neu-
rological outcome based on Glasgow Outcome Scale29.
Figure 3. Diagnostic accuracy of biomarkers predicts brain death. Area under the receiver-operating characteristic curve (AUC) for CSF glutamate
(A) and lactate (B) concentrations. ROC curves based on glutamate and lactate were used as a predictor of death in TBI patients. The cutoff for
glutamate was set at >57.75, providing 80% of sensitivity and 84.62% of specificity (AUC: 0.8214, 95% CI, CL: 54.55–98.08%). The cutoff for
lactate was set at >4.650, providing 100% of sensitivity and 85.71% of specificity (AUC: 0.8810, 95% CI, CL: 54.55–98.08%). Both biomarkers
presented high specificity and sensitivity for discriminating TBI survival and nonsurvival patients.
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Moreover, there is strong evidence showing that impaired
cerebrovascular pressure reactivity, and decreased brain
perfusion and oxygenation, are forces driving metabolic
abnormalities related to lactate/pyruvate ratio. However,
this oxygen deficiency is more pronounced in the perile-
sional tissue26,30 and apparently does not explain the
metabolic alterations in the whole brain after a TBI.
Indeed, increased lactate production in the injured brain
seems to be independent of oxygen availability, and there-
fore cannot be considered as a direct ischemic and
hypoxic metabolic marker30. Instead, experimental and
clinical studies highlight the existence of an acute hyper-
glycolysis after severe TBI followed by subacute decrease
in glucose metabolism.31,32 The early hyperglycolytic
phase seems to reflect the energy demands for reversal of
ionic imbalances caused by massive release of glutamate33,
while in subacute phase, the decrease in glucose utiliza-
tion may indicate impaired mitochondrial function.33,34
Interestingly, we found a significant correlation
between lactate and glutamate levels indicating they are
strongly and positively associated. In comparison to our
findings in CSF, Bouzat et al., 201416 demonstrated that
hypertonic infusion of lactate in severe TBI patients
improved metabolic profile and decreased glutamate levels
in the brain extracellular microdyalisate. In addition, a
previous study in severe TBI patients showed that brain
glucose availability decreases locally and lactate increases
in the absence of ischemia. In contrast, our study, sug-
gests that lactate production may significantly increase
even in the presence of a satisfactory glucose supply
(Table 1) to attend brain metabolic needs. However, as
proposed by Lama et al., 201428, the acute increase in the
brain tissue lactate concentrations after severe TBI is asso-
ciated to decreased neuronal uptake, probably leading to
irreversible injury and pan-necrosis. Therefore, although
the high extracellular availability of lactate suggests that
Figure 4. Association between biomarkers indexed by cross-correlation analyses. (A) Symmetric matrix of correlation coefficient values between
biomarkers; (B) Symmetric matrix of – values between biomarkers; (C) Binary matrix corrected by Bonferroni method at P < 0.05; (D) Network for
the biomarkers indicating high levels of associations between glutamate, lactate and BDNF.
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the metabolic machinery in astrocytes was responsive to
the increased energy demands after TBI, neurons were
apparently not capable of using lactate as substrate, ulti-
mately contributing to the patient’s death. This highlights
a putative role for the monocarboxylated transporters
expression in the metabolic uncoupling and neuronal
death after severe TBI. From the clinical perspective, we
propose that short-term elevation of CSF glutamate and
lactate levels after severe TBI has strong predictive value
for unfavorable neurological outcome. Moreover, lactate
and glutamate positively correlated with long-term dis-
ability grade scale mRS).
In addition, we also assessed the ability of neu-
rotrophins BDNF and GDNF in interrogate clinical out-
comes in severe TBI patients. Data from preclinical
studies indicate that BDNF modulates vesicular glutamate
release and NMDA receptor sensitivity35,36, and the avail-
ability of lactate for neurons through the monocarboxy-
late transporters-2.21 As a CSF biomarker, BDNF
displayed significant correlations with both glutamate and
lactate; however, it was not predictive of imminent death
within 3 days of hospitalization as were glutamate and
lactate levels. Actually, measurements of BDNF levels in
plasma and serum of severe TBI patients have provided
controversial results. Simon et al., 2016 reported no pre-
dictive value for BDNF to discriminate survival and non-
survival patients.37 Similar to our findings, day-of-injury
serum BDNF was associated with TBI diagnosis; however,
the authors also showed 6-month prognostic value
regarding recovery from TBI.38 Further, the CSF levels of
BDNF predicted mortality within 7 days of hospitalization
after severe TBI.39 Though preclinical studies proposes
GDNF as therapeutic strategy to treat TBI, which high-
lights a neurobiological importance, its clinical value as
fluid biomarker in patients has been little explored. In
our study, CSF GDNF level was not a good diagnostic or
predictive biomarker of poor clinical outcome. The main
limitation of this study was the small sample size. Further,
due to logistic difficulties, we did not have access to the
biological samples of patients posthospitalization.
The CSF levels of glutamate and lactate have potential
prognostic value to discriminate with high sensitivity and
specificity severe TBI patients who will evolve to death
within 3 days after hospitalization. Glutamate and lactate
are promising CSF biomarkers of death after severe TBI.
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